Applied Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Applied Therapeutics, Inc. has been acquired by Cycle Group Holdings Limited for approximately $14.3 million, with shareholders receiving cash and contingent value rights.
Applied Therapeutics agrees to be acquired by Cycle Group Holdings for $0.088 per share in cash plus contingent value rights tied to drug development and sales milestones, alongside an $8.5 million unsecured loan.
Applied Therapeutics, Inc. has initiated a comprehensive review of strategic alternatives to maximize shareholder value, alongside a significant workforce reduction.
Applied Therapeutics reported a significantly reduced net loss in Q3 2025, alongside ongoing regulatory discussions for govorestat in rare diseases and a board leadership change.
Applied Therapeutics, Inc. has entered into a new 'at-the-market' equity offering agreement with Cantor Fitzgerald & Co. for up to $75 million, replacing a prior agreement.
Applied Therapeutics, Inc. received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, resulting in a transfer to the Nasdaq Capital Market.
Applied Therapeutics, Inc. reported a significant net loss in the second quarter of 2025, alongside positive clinical advancements for its lead drug candidate govorestat in rare diseases and strategic corporate developments.
Applied Therapeutics, Inc. announced preliminary unaudited stockholders' equity of $17.4 million as of June 30, 2025, while actively addressing a Nasdaq delisting threat due to its stock price.
Applied Therapeutics, Inc. has appointed Dr. Evan P. Bailey as its new Chief Medical Officer, succeeding Dr. Riccardo Perfetti, while also reporting mixed but promising long-term clinical results for its lead drug candidate, govorestat, in the INSPIRE Phase 2/3 trial for CMT-SORD Deficiency.
Applied Therapeutics, Inc. stockholders approved a reverse stock split, the election of a Class III director, auditor ratification, and executive compensation at their 2025 Annual Meeting.
Applied Therapeutics announces its first quarter 2025 financial results, focusing on the advancement of govorestat for rare diseases and upcoming data presentations.
Applied Therapeutics reports its Q4 and year-end 2024 financial results, highlighting key executive appointments and ongoing development program reviews.
Applied Therapeutics received a notification from Nasdaq on February 7, 2025, indicating non-compliance with the minimum bid price requirement due to its stock price falling below $1.00 for 30 consecutive business days.
8-K: Applied Therapeutics Announces Leadership Changes, Appoints New Executive Chairman and Interim CEO
Applied Therapeutics has appointed John H. Johnson as Executive Chairman and Les Funtleyder as interim CEO, while Shoshana Shendelman steps down from her roles.
Joel Marcus has resigned from the Board of Directors of Applied Therapeutics, effective immediately, prompting a search for a new independent director.
Applied Therapeutics received a warning letter from the FDA related to electronic data capture and a dosing error in a study for their drug govorestat, despite the company's belief that these issues had been previously addressed.
The FDA has issued a Complete Response Letter for Applied Therapeutics' New Drug Application for govorestat, citing deficiencies in the clinical application.
Applied Therapeutics announced its third quarter 2024 financial results and provided updates on the regulatory progress of its lead drug candidate, govorestat, for the treatment of Classic Galactosemia and SORD Deficiency.
Applied Therapeutics reported its second quarter 2024 financial results, highlighting regulatory advancements for govorestat in treating Classic Galactosemia and SORD Deficiency.
Applied Therapeutics held its 2024 Annual Meeting of Stockholders on June 6, 2024, where key proposals including the election of directors, ratification of the auditor, and an increase in authorized shares were approved.
Applied Therapeutics announced its first quarter 2024 financial results, highlighting regulatory advancements for govorestat and progress in other clinical programs.
Applied Therapeutics has appointed Dale Hooks as its new Chief Commercial Officer, effective April 12, 2024, replacing Adam Hansard, whose employment terminated on the same day.
The FDA has extended the review period for Applied Therapeutics' govorestat (AT-007) for Classic Galactosemia by three months, setting a new target date of November 28, 2024.
Applied Therapeutics released a corporate presentation and positive interim 12-month results from its Phase 3 INSPIRE trial for SORD Deficiency, showcasing the potential of its lead drug candidate, govorestat.
Applied Therapeutics reports positive clinical trial results for govorestat in SORD Deficiency and Galactosemia, secures $100 million in private placement, and anticipates extended cash runway into 2026.
Applied Therapeutics has successfully raised $100 million through a private placement to fund its research and development efforts and commercialization plans.
Applied Therapeutics reports positive 12-month interim results from its Phase 3 INSPIRE trial for govorestat, a potential treatment for SORD Deficiency.